Literature DB >> 10210376

Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery.

M M Walther1, P L Choyke, G Glenn, J C Lyne, W Rayford, D Venzon, W M Linehan.   

Abstract

PURPOSE: Patients with hereditary forms of renal cancer are at risk for new tumors and metastases. Renal parenchymal sparing surgery has been performed to preserve renal function and quality of life, and prevent metastases. We evaluated a 3 cm. threshold for performing renal parenchymal sparing surgery in patients with von Hippel-Lindau disease and hereditary papillary renal cancer.
MATERIALS AND METHODS: Patients with von Hippel-Lindau disease or hereditary papillary renal cancer and renal cancer were identified by screening affected kindred and by kindred history. Patients with small tumors were followed with serial imaging studies until the largest renal tumor was 3 cm., when renal parenchymal sparing surgery was performed. Renal tumors greater than 3 cm. were resected without delay. Parenchymal sparing techniques were used when possible in each group.
RESULTS: The 3 cm. surgical threshold was evaluated in 52 patients with von Hippel-Lindau disease (group 1) at a median followup of 60 months (range 6 to 205). None of these patients had metastatic disease and none has required renal transplantation or dialysis. In 44 patients with von Hippel-Lindau disease (group 2) renal tumors larger than 3 cm. developed. Median followup from the initial radiological diagnosis of renal cancer in this group was 66.5 months (range 0 to 321). Patients in group 1 underwent parenchymal sparing surgery instead of nephrectomy more frequently than those in group 2 (46 of 48 operations or 96% versus 45 of 72 or 63%, Fisher's exact test p <0.0001). In contrast to patients in group 1, metastatic renal cancer developed in 11 of the 44 in group 2 (25%) (Fisher's exact test p <0.0001). A total of 23 patients with hereditary papillary renal cancer were also identified. Median followup in these cases was 44 months (range 0 to 237). Ten patients had tumors less than 3 cm. No patient with tumors less than 3 cm. and 2 of the 13 (15%) with larger tumors had metastases.
CONCLUSIONS: Using a 3 cm. renal tumor diameter as an indication for renal surgery no patient with renal cancer and von Hippel-Lindau disease or hereditary papillary renal cancer had metastatic disease regardless of the number of tumors. Using a lesion size of 3 cm. as a threshold for performing renal parenchymal sparing surgery may help to prevent metastatic disease, unnecessary renal damage due to frequent surgery and renal dialysis or transplantation.

Entities:  

Mesh:

Year:  1999        PMID: 10210376     DOI: 10.1016/s0022-5347(05)68930-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  59 in total

Review 1.  Management of locally recurrent kidney cancer.

Authors:  Eric A Singer; Gennady Bratslavsky
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

Review 2.  Long-term management of bilateral, multifocal, recurrent renal carcinoma.

Authors:  Gennady Bratslavsky; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

3.  Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit.

Authors:  Amaka T Fadahunsi; Thomas Sanford; W Marston Linehan; Peter A Pinto; Gennady Bratslavsky
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

4.  Neurologic manifestations of von Hippel-Lindau disease.

Authors:  John A Butman; W Marston Linehan; Russell R Lonser
Journal:  JAMA       Date:  2008-09-17       Impact factor: 56.272

5.  Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.

Authors:  Maria I Carlo; A Ari Hakimi; Grant D Stewart; Gennady Bratslavsky; James Brugarolas; Ying-Bei Chen; W Marston Linehan; Eamonn R Maher; Maria J Merino; Kenneth Offit; Victor E Reuter; Brian Shuch; Jonathan A Coleman
Journal:  Eur Urol       Date:  2019-07-18       Impact factor: 20.096

Review 6.  Genetic predisposition to kidney cancer.

Authors:  Laura S Schmidt; W Marston Linehan
Journal:  Semin Oncol       Date:  2016-09-22       Impact factor: 4.929

7.  Re: Csaba Berczi, Ben Thomas, Zsolt Bacso, Tibor Flasko. Bilateral renal cancers: oncological and functional outcomes. Int Urol Nephrol 2016 (Epub ahead of print).

Authors:  Matthew J Watson; Abhinav Sidana; Eric A Singer; Gopal N Gupta; Ardeshir R Rastinehad; Srinivas Vourganti; Gennady Bratslavsky; Adam R Metwalli
Journal:  Int Urol Nephrol       Date:  2016-10-27       Impact factor: 2.370

8.  Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up.

Authors:  C A Jilg; Hartmut P H Neumann; S Gläsker; O Schäfer; C Leiber; P U Ardelt; M Schwardt; W Schultze-Seemann
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

Review 9.  Molecular diagnosis and therapy of kidney cancer.

Authors:  W Marston Linehan; Gennady Bratslavsky; Peter A Pinto; Laura S Schmidt; Len Neckers; Donald P Bottaro; Ramaprasad Srinivasan
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

Review 10.  The clinical implications of the genetics of renal cell carcinoma.

Authors:  Inger Rosner; Gennady Bratslavsky; Peter A Pinto; W Marston Linehan
Journal:  Urol Oncol       Date:  2009 Mar-Apr       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.